AzurRx BioPharma Identifies Asymchem as Potential Partner of Choice for MS1819 Phase 3 Clinical Trial Drug Production
November 10, 2020 08:00 ET
|
AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., Nov. 10, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic,...
AzurRx BioPharma Activates Additional Clinical Trial Sites in Turkey for Phase 2 Combination Therapy Trial of MS1819 in Cystic Fibrosis
October 14, 2020 08:00 ET
|
AzurRx BioPharma, Inc.
Two clinical trial sites activated in Turkey, with patient screening initiatedFollows activation of six clinical sites in Hungary and dosing of first eight patientsTopline data expected in Q2 2021 ...
AzurRx BioPharma Announces Two Abstracts Accepted for Presentation at the 2020 North American Cystic Fibrosis Virtual Conference
September 15, 2020 08:00 ET
|
AzurRx BioPharma, Inc.
Abstracts to Focus on: Results from Phase 2, Open-Label, Multicenter, 2x2 Cross-Over Trial to Assess Safety and Efficacy of MS1819 in Patients with Exocrine Pancreatic Insufficiency Due to Cystic...
AzurRx BioPharma to Present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference (September 14) and the LD 500 Virtual Conference (September 4)
August 31, 2020 08:00 ET
|
AzurRx BioPharma, Inc.
NEW YORK, Aug. 31, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies...
AzurRx BioPharma Initiates European Arm of Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis
August 17, 2020 08:00 ET
|
AzurRx BioPharma, Inc.
Three clinical trial sites activated in Poland, with patient screening initiatedFollows activation of six clinical sites in the U.S. and dosing of first three patientsTopline data expected in Q1 2021 ...
AzurRx BioPharma Initiates Phase 2b Clinical Trial of MS1819 in Cystic Fibrosis – with First Patient Screened and Three Clinical Trial Sites Activated
July 22, 2020 08:00 ET
|
AzurRx BioPharma, Inc.
Three OPTION 2 clinical trial sites activated in the U.S.Topline data expected in Q1 2021 NEW YORK, July 22, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the...